



*Ex. Co. Secretariat:* please complete this copy by insertion of signatures and date of making, and send to Legislative Services Section, Legislative Drafting Division, Attorney-General's Department.



Statutory Rules 1981 No. 1

345/

## National Health (Pharmaceutical Benefits) Regulations<sup>2</sup> (Amendment)

WHEREAS it is provided by sub-section 101(4) of the *National Health Act* 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that each of the following drugs or medicinal preparations be prescribed as a pharmaceutical benefit under section 85 of that Act, namely—

- (a) Bromocriptine Mesylate;
- (b) Dextran 70;
- (c) Dipivefrin Hydrochloride;
- (d) Gliclazide;
- (e) Mianserin Hydrochloride;
- (f) Trimipramine; and
- (g) Tri-potassium Di-citrato Bismuthate Complex;

AND WHEREAS it is desirable, amongst other things, to prescribe each of those drugs or medicinal preparations as a pharmaceutical benefit under that section:

NOW THEREFORE I, the Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the *National Health Act* 1953.

Dated 26 November 1981.

**ZELMAN COWEN**

Governor-General

By His Excellency's Command,

(sgd) Michael Mackellar

Minister of State for Health

**Commencement**

1. These Regulations shall come into operation on 1 December 1981.

**Schedule 1**

2. Schedule 1 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

**Schedule 2**

3. Schedule 2 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

**Schedule 3**

4. Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

**Schedule 5**

5. Schedule 5 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

**SCHEDULE 1**

Regulation 2

AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH  
(PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 507.
2. After item 639 insert the following item:  
"639A Neostigmine Methylsulphate".
3. After item 718 insert the following item:  
"718A Pentolinium Injection".

**SCHEDULE 2**

Regulation 3

AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH  
(PHARMACEUTICAL BENEFITS) REGULATIONS

1. After item 82 insert the following item:  
"82A Dextran 70 . . . . . Hypromellose 4500 with Dextran 70".
2. After item 98 insert the following item:  
"98A Dipivefrin Hydrochloride . . . . .".
3. Omit item 143, substitute the following item:  
"143 Hypromellose 4500 . . . . . Dextran 70 with Hypromellose 4500".
4. Omit item 174.
5. Omit item 194.
6. After item 245 insert the following item:  
"245A Tri-potassium Di-citrate Bismuthate Complex . . . . .".

**SCHEDULE 3**

Regulation 4

**AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH  
(PHARMACEUTICAL BENEFITS) REGULATIONS**

1. After item 43 insert the following item:  
"43A Bromocriptine Mesylate".
2. After item 83 insert the following item:  
"83A Dextran 70".
3. After item 93 insert the following item:  
"93A Dipivefrin Hydrochloride".
4. After item 113 insert the following item:  
"113A Gliclazide".
5. After item 178 insert the following item:  
"178A Mianserin Hydrochloride".
6. Omit item 211.
7. After item 284 insert the following item:  
"284A Trimipramine".
8. After item 285 insert the following item:  
"285A Tri-potassium Di-citrato Bismuthate Complex".

**SCHEDULE 4**

Regulation 5

**AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH  
(PHARMACEUTICAL BENEFITS) REGULATIONS**

1. After item 15 insert the following items:
 

<p>"15A Bromocriptine Mesylate, Tablets 2.5 mg . . . . ."</p> <p style="padding-left: 2em;">15B Bromocriptine Mesylate, Capsules 10 mg . . . . ."</p>	<p>With the written authority of the Permanent Head - Pathological hyperprolactinaemia where appropriate surgery or radiotherapy are not indicated or have already been used with incomplete resolution</p> <p>With the written authority of the Permanent Head - Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate".</p>
---	--
2. Omit item 37, substitute the following item:
 

<p>"Cholestyramine . . . . ."</p>	<p>With the written authority of the Permanent Head - Bile salt malabsorption associated with ileal resection or proven ileal disease Pruritus associated with partial biliary obstruction not responding to other therapy Hypercholesterolaemia".</p>
-----------------------------------	--
3. Omit item 39A, substitute the following item:
 

<p>"39A Clofibrate Capsules, B.P. . . . ."</p>	<p>With the written authority of the Permanent Head - Hypertriglyceridaemia Hypercholesterolaemia".</p>
--	---
4. After item 43 insert the following item:
 

<p>"43A Codeine Phosphate, B.P. with Paracetamol, B.P. Tablets 8 mg - 500 mg . . . . ."</p>	<p>For pensioners only".</p>
---	------------------------------

## SCHEDULE 4 - continued

5. Omit item 44, substitute the following item:  
 "44 Colestipol Hydrochloride . . . . . With the written authority of the Permanent Head -- Hypercholesterolaemia".
6. Omit item 109.
7. After item 110 insert the following item:  
 "110A Mianserin Hydrochloride . . . . . With the written authority of the Permanent Head -- Depressive illness in persons with cardiovascular disease".
8. Omit item 156, substitute the following item:  
 "156 (1) Sodium Valproate Syrup  
 (2) Sodium Valproate Tablet 200 mg  
 Epilepsy".
9. After item 156 insert the following item:  
 "156A Sodium Valproate Tablet 500 mg (enteric coated) . . . . . With the written authority of the Permanent Head -- Epilepsy in patients requiring more than 1g of sodium valproate daily".
10. Omit item 160, substitute the following item:  
 "160 Sulindac . . . . . With the written authority of the Permanent Head -- Chronic rheumatoid arthritis not responding to other non-steroidal anti-inflammatory drugs (disregarding phenylbutazone)  
 Chronic osteoarthritis not responding to other non-steroidal anti-inflammatory drugs (disregarding phenylbutazone)".
11. After item 176 insert the following item:  
 "176A Trimipramine . . . . . With the written authority of the Permanent Head -- Endogenous depression where there is an inadequate response to not less than 100 mg of trimipramine daily".
12. After item 177 insert the following item:  
 "177A Tri-potassium Di-citrate Bismuthate Complex . . . . . With the written authority of the Permanent Head -- Duodenal ulcer confirmed by radiology, endoscopy or surgery  
 Gastric ulcer confirmed by radiology, endoscopy, or surgery".

## NOTES

1. Notified in the *Commonwealth of Australia Gazette* on L 1981. 30 November/
2. Statutory Rules 1967 No. 17 as amended to date. For previous amendments see Note 2 to Statutory Rules 1981 No. 52 and see also Statutory Rules 1981 Nos. 52, 212 and 218.

Printed by Authority by the Commonwealth Government Printer